SCHEMBL6093009

SCHEMBL6093009

N[C@H]1CCN2c3c(cccc31)C(=O)N[C@@H]2c1ccc(OCCO)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR174 Q9BXC1 1/20 0.36
ESR1 P03372 5/20 0.34
ESR2 Q92731 2/20 0.34
KEAP1 Q14145 4/20 0.34
PARP1 P09874 2/20 0.33
HRH3 Q9Y5N1 2/20 0.33
NFE2L2 Q16236 1/20 0.33
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 1/20 0.33
USP2 O75604 1/20 0.33
GAA P10253 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
PDE6D O43924 1/20 0.32
TNKS2 Q9H2K2 1/20 0.31
PLA2G1B P04054 1/20 0.31
MAPT P10636 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6090472 1.00 GPR174 (0.36) GPR174ESR1ESR2KEAP1PARP1
SCHEMBL6091022 0.87 PARP1 (0.40) ESR1PARP1HRH3ALDH1A1KDM4E
SCHEMBL6091436 0.87 PARP1 (0.40) ESR1PARP1HRH3ALDH1A1KDM4E
SCHEMBL6092971 0.85 KDM4E (0.42) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL6089125 0.85 KDM4E (0.42) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL6091289 0.85 KDM4E (0.42) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL6089444 0.85 KDM4E (0.42) ALDH1A1KDM4EGAAMEN1KMT2A
Hydrochloric Acid SCHEMBL6091722 0.84 KDM4E (0.41) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL6091091 0.83 ALDH1A1 (0.44) ALDH1A1KDM4EUSP2GAAHSD17B10
SCHEMBL6090522 0.83 ALDH1A1 (0.44) ALDH1A1KDM4EUSP2GAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004028-A1 Novel PARP inhibitor MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1582520-A1 NOVEL PARP INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2005-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004028-A1 Novel PARP inhibitor PARP1, PARP2, PARP11 GPR174 3747/4885ESR1 2745/4885ESR2 4246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.